Skip to content

Number of Previous Cesarean Sections on the Results of Angiogenic Factors.

Effect of Number of Previous Cesarean Sections on the Results of Angiogenic Factors. A Descriptive, Prospective Study.

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06166303
Enrollment
540
Registered
2023-12-12
Start date
2025-10-01
Completion date
2026-03-30
Last updated
2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section

Keywords

Cesarean section, Angiogenic factors, Preeclampsia

Brief summary

Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries. The only cure for THE is termination of pregnancy, which ends up being a decision in which gestational age and maternal risks must be balanced. Angiogenic factors have come to occupy an indispensable place in the arsenal of tools that can be used to separate the patient with a high likelihood of complications from those in whom prolongation of pregnancy could represent an important neonatal benefit. Although the usefulness of angiogenic factors in these scenarios is known, little is known about the effects that other conditions might have on their serum levels, mainly those that have an effect on trophoblastic invasion, the process that initiates implantation of the pregnancy in the endometrium. The purpose of the present study is to assess the effect that a history of uterine surgery, such as caesarean section, might have on angiogenic factor scores in subjects with no history of a hypertensive disorder of pregnancy.

Interventions

DIAGNOSTIC_TESTsFlt-1/PGIF

Index of sFlt-1/PGIF

Sponsors

Saint Thomas Hospital, Panama
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 36 weeks of gestation or more * Singleton pregnancy * Previous cesarean section (case)

Exclusion criteria

* Vasculitis * Twin pregnancy * Chronic endometritis * Smoking * Lupus * Renal failure * Liver disease * Thrombocytopenia

Design outcomes

Primary

MeasureTime frameDescription
Index sFlt-1/PIGFFrom the moment of randomization up until delivery. Between 24-48 hours.Angiogenic factors, normal value.

Secondary

MeasureTime frameDescription
Progression to preeclampsiaUp until discharge. On average, 7 daysNumber of subjects that develop a preeclampsia

Countries

Panama

Contacts

Primary ContactOsvaldo Reyes, MD
oreyespanama@yahoo.es+507 65655041

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026